Bioresorbable Scaffolds: Unfulfilled Prophecies

Affiliations

Editorial

Lorenz Räber et al. Circulation. 2019.

. 2019 Dec 3;140(23):1917-1920.

doi: 10.1161/CIRCULATIONAHA.119.043773. Epub 2019 Sep 25.

¹ Department of Cardiology, Bern University Hospital, University of Bern, Switzerland.

No abstract available

Keywords: Editorials; coronary artery disease; percutaneous coronary intervention; stents.

Comment on

A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial.
Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. Ormiston JA, et al. Lancet. 2008 Mar 15;371(9616):899-907. doi: 10.1016/S0140-6736(08)60415-8. Lancet. 2008. PMID: 18342684 Clinical Trial.
Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial.
Kereiakes DJ, Ellis SG, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, Tan SH, Ediebah DE, Simonton C, Stone GW; ABSORB III Investigators. Kereiakes DJ, et al. Circulation. 2019 Dec 3;140(23):1895-1903. doi: 10.1161/CIRCULATIONAHA.119.042584. Epub 2019 Sep 25. Circulation. 2019. PMID: 31553222